An international research team with strong participation from DTU has developed a new biotechnological platform that makes it ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The therapy in question, dubbed C-CAR031, is based on AstraZeneca’s own ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of ...

Researchers at the University of Chicago have developed a "universal" chimeric antigen receptor (CAR) platform that offers enhanced safety, adaptability, and the potential to overcome long-standing ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...

In vivo CAR T-cell therapies could improve access by eliminating complex logistics and reducing costs, making them more accessible to underserved populations. Traditional CAR T-cell therapies face ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...